Summary
EudraCT Number:2016-000869-23
Sponsor's Protocol Code Number:
National Competent Authority:UK - MHRA
Clinical Trial Type:EEA CTA
Trial Status:GB - no longer in EU/EEA
Date on which this record was first entered in the EudraCT database:2016-09-23
Trial results
A. Protocol Information
A.1Member State ConcernedUK - MHRA
A.2EudraCT number2016-000869-23
A.3Full title of the trial
Targeting cancer care with the use of genetic profiling
A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
The BARCODE 2 Study – The Use of Genetic Profiling to Guide Prostate Cancer Treatment
A.3.2Name or abbreviated title of the trial where available
BARCODE 2
A.4.1Sponsor's protocol code number
A.7Trial is part of a Paediatric Investigation Plan No
A.8EMA Decision number of Paediatric Investigation Plan
B. Sponsor Information
B.Sponsor: 1
B.1.1Name of SponsorThe Institute of Cancer Research
B.1.3.4CountryUnited Kingdom
B.3.1 and B.3.2Status of the sponsorNon-Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1Name of organisation providing supportEuropean Research Council
B.4.2CountryUnited Kingdom
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1Name of organisationThe Institute of Cancer Research
B.5.2Functional name of contact pointProf Rosalind Eeles
B.5.3 Address:
B.5.3.1Street AddressThe Institute of Cancer Research
B.5.3.2Town/ city15 COTSWOLD RD
B.5.3.3Post codeSM2 5NG
B.5.3.4CountryUnited Kingdom
B.5.4Telephone number02087224094
B.5.6E-mail[email protected]
D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3IMP RoleTest
D.2 Status of the IMP to be used in the clinical trial
D.2.1IMP to be used in the trial has a marketing authorisation Information not present in EudraCT
D.2.1.1.2Name of the Marketing Authorisation holderHospira UK Limited
D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
D.2.5.1Orphan drug designation number
D.3 Description of the IMP
D.3.1Product nameCarboplatin
D.3.4Pharmaceutical form Solution for infusion
D.3.4.1Specific paediatric formulation No
D.3.7Routes of administration for this IMPIntravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8INN - Proposed INNCarboplatin
D.3.9.1CAS number 41575-94-4
D.3.9.4EV Substance CodeAS4
D.3.10 Strength
D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
D.3.10.2Concentration typeequal
D.3.10.3Concentration number10 mg/ml
D.3.11 The IMP contains an:
D.3.11.1Active substance of chemical origin Yes
D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
The IMP is a:
D.3.11.3Advanced Therapy IMP (ATIMP) No
D.3.11.3.1Somatic cell therapy medicinal product No
D.3.11.3.2Gene therapy medical product No
D.3.11.3.3Tissue Engineered Product No
D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
D.3.11.5Radiopharmaceutical medicinal product No
D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
D.3.11.7Plasma derived medicinal product No
D.3.11.8Extractive medicinal product No
D.3.11.9Recombinant medicinal product No
D.3.11.10Medicinal product containing genetically modified organisms No
D.3.11.11Herbal medicinal product No
D.3.11.12Homeopathic medicinal product No
D.3.11.13Another type of medicinal product No
D.8 Information on Placebo
D.8 Placebo: 1
D.8.1Is a Placebo used in this Trial?Yes
E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1Medical condition(s) being investigated
Prostate Cancer
E.1.1.1Medical condition in easily understood language
Prostate Cancer
E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
MedDRA Classification
E.1.2 Medical condition or disease under investigation
E.1.2Version 19.0
E.1.2Level PT
E.1.2Classification code 10062904
E.1.2Term Hormone-refractory prostate cancer
E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
E.1.3Condition being studied is a rare disease No
E.2 Objective of the trial
E.2.1Main objective of the trial
To determine the response rate to two cycles of platinum chemotherapy in patients with metastatic castration resistant prostate cancer (mCRPC) and a germline mutation in a DNA repair gene.
E.2.2Secondary objectives of the trial
•To assess progression-free and overall survival of patients with mCRPC and a DNA repair gene mutation after treatment with carboplatin.
•To determine the rate of germline DNA repair gene mutations in patients with mCRPC.
E.2.3Trial contains a sub-study No
E.3Principal inclusion criteria
For Part 1 (genetic screening) of the study:
1.Age ≥ 18 years.
2.Histologically confirmed prostate adenocarcinoma. A copy of the original histology report from biopsy or surgery must be obtained.
3.Castration-resistant disease defined as biochemical or radiological progression on/after treatment with orchidectomy or LHRH analogues as per PCWG2 criteria.
4.Confirmed metastatic disease on conventional imaging methods such as CT, bone scan or PET imaging.
5.Current or previous treatment including docetaxel and/or enzalutamide/ abiraterone
6.Adequate renal function measured by calculated GFR (Cockcroft-Gault) >30ml/min. This must be documented within 7 days of registration. If a patient had renal dysfunction that is expected to improve, they may be considered for part 1 of the study
7.Adequate haematological function (haemoglobin ≥10g/dl, neutrophil count >1.5x109/L and platelets >100x109/L). This must be documented within 7 days of registration.
8.WHO performance status 0-2 as assessed and documented by study doctor.
9.Life expectancy >12 weeks
10.Patients with stable, treated brain metastases will be eligible providing informed consent can be given and that other sites of measurable disease are present
11.The subject is capable of understanding and complying with the protocol requirements and has signed the BARCODE 2 informed consent form.

In addition to the above, for Part 2 of the study:
1.Confirmed pathogenic germline mutation in a DNA repair gene. (Patients with a known germline mutation will need to provide a report from the external laboratory where genetic testing was carried out)
2.Previous treatment with docetaxel and abiraterone or enzalutamide with documented disease progression prior to study entry to part 2 (rising PSA and/or radiographic progression)
3.Adequate liver function: Total bilirubin ≤1.5 x upper limit of normal (ULN) except for patients with known Gilbert’s syndrome; AST and ALT ≤ 2.5x ULN in the presence of liver metastases.
4.Adequate renal function: creatinine clearance >40ml/min measured by EDTA clearance.
E.4Principal exclusion criteria
Exclusion Criteria (for part 1 and 2)
1.Critical organ metastases (e.g. spinal metastases with risk of cord compression) as documented on most recent imaging report.
2.Patients with bleeding tumours.
3.Previous treatment with a platinum chemotherapy drug for prostate cancer.
4.Previous treatment with a PARP inhibitor
5.Patients with a history of severe allergic to carboplatin or other platinum-containing compounds
6.Patients unfit for chemotherapy or those with ongoing neuropathy >grade 1 (sensory or motor) according to NCI CTCAE V4.02.
7.Known and documented hearing impairment
8.Other active malignancies or previous malignancies likely, in the PI’s opinion, to impact on management of mCRPC.
9.Significant documented cardiovascular disease: severe/unstable angina, myocardial infarction less than 6 months prior to trial entry, arterial thrombotic events less than 6 months prior to trial entry, clinically significant cardiac failure requiring treatment (NYHA II-IV).
10.Cerebrovascular disease (CVA or TIA) in the preceding 2 years to entry to Part 2 of study.
11.Presence of symptomatic brain metastases.
E.5 End points
E.5.1Primary end point(s)
Response rate to two cycles of platinum chemotherapy in patients with mCRPC and germline DNA repair gene mutations based on CT imaging using RECIST 1.1 criteria, and/or fall in PSA of >50%.
E.5.1.1Timepoint(s) of evaluation of this end point
The primary endpoint will be evaluated approximately 6 weeks after the first dose of carboplatin chemotherapy (i.e. 3 weeks after the second dose of carboplatin).
E.5.2Secondary end point(s)
• The incidence of germline mutations in DNA repair genes in a population of mCRPC cases.
• Overall survival and progression free survival of patients with mCRPC and a DNA repair gene mutation treated with carboplatin.
• Cause specific survival from date of first diagnosis of prostate cancer in patients with germline DNA repair gene mutations
• Radiographic PFS
• Time to radiographic progression
• Time to PSA progression
• Duration and pattern of PSA response
E.5.2.1Timepoint(s) of evaluation of this end point
Imaging and blood tests for secondary endpoints will be carried out approximately every 9 weeks. Survival follow up after completion of treatment will be carried out every 3 months.
E.6 and E.7 Scope of the trial
E.6Scope of the trial
E.6.1Diagnosis No
E.6.2Prophylaxis No
E.6.3Therapy Yes
E.6.4Safety No
E.6.5Efficacy Yes
E.6.6Pharmacokinetic No
E.6.7Pharmacodynamic No
E.6.8Bioequivalence No
E.6.9Dose response No
E.6.10Pharmacogenetic No
E.6.11Pharmacogenomic No
E.6.12Pharmacoeconomic No
E.6.13Others No
E.7Trial type and phase
E.7.1Human pharmacology (Phase I) No
E.7.1.1First administration to humans No
E.7.1.2Bioequivalence study No
E.7.1.3Other No
E.7.1.3.1Other trial type description
E.7.2Therapeutic exploratory (Phase II) Yes
E.7.3Therapeutic confirmatory (Phase III) No
E.7.4Therapeutic use (Phase IV) No
E.8 Design of the trial
E.8.1Controlled No
E.8.1.1Randomised No
E.8.1.2Open No
E.8.1.3Single blind No
E.8.1.4Double blind No
E.8.1.5Parallel group No
E.8.1.6Cross over No
E.8.1.7Other No
E.8.2 Comparator of controlled trial
E.8.2.1Other medicinal product(s) Information not present in EudraCT
E.8.2.2Placebo Information not present in EudraCT
E.8.2.3Other Information not present in EudraCT
E.8.3 The trial involves single site in the Member State concerned Yes
E.8.4 The trial involves multiple sites in the Member State concerned No
E.8.4.1Number of sites anticipated in Member State concerned1
E.8.5The trial involves multiple Member States No
E.8.6 Trial involving sites outside the EEA
E.8.6.1Trial being conducted both within and outside the EEA No
E.8.6.2Trial being conducted completely outside of the EEA No
E.8.7Trial has a data monitoring committee No
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
Date of last data capture, to gather data needed for evaluation of all endpoints
E.8.9 Initial estimate of the duration of the trial
E.8.9.1In the Member State concerned years3
E.8.9.1In the Member State concerned months4
E.8.9.1In the Member State concerned days1
E.8.9.2In all countries concerned by the trial years3
E.8.9.2In all countries concerned by the trial months4
E.8.9.2In all countries concerned by the trial days1
F. Population of Trial Subjects
F.1 Age Range
F.1.1Trial has subjects under 18 No
F.1.1Number of subjects for this age range: 0
F.1.1.1In Utero No
F.1.1.1.1Number of subjects for this age range: 0
F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
F.1.1.2.1Number of subjects for this age range: 0
F.1.1.3Newborns (0-27 days) No
F.1.1.3.1Number of subjects for this age range: 0
F.1.1.4Infants and toddlers (28 days-23 months) No
F.1.1.4.1Number of subjects for this age range: 0
F.1.1.5Children (2-11years) No
F.1.1.5.1Number of subjects for this age range: 0
F.1.1.6Adolescents (12-17 years) No
F.1.1.6.1Number of subjects for this age range: 0
F.1.2Adults (18-64 years) Yes
F.1.2.1Number of subjects for this age range: 40
F.1.3Elderly (>=65 years) Yes
F.1.3.1Number of subjects for this age range: 14
F.2 Gender
F.2.1Female No
F.2.2Male Yes
F.3 Group of trial subjects
F.3.1Healthy volunteers No
F.3.2Patients Yes
F.3.3Specific vulnerable populations No
F.3.3.1Women of childbearing potential not using contraception No
F.3.3.2Women of child-bearing potential using contraception No
F.3.3.3Pregnant women No
F.3.3.4Nursing women No
F.3.3.5Emergency situation No
F.3.3.6Subjects incapable of giving consent personally No
F.3.3.7Others No
F.4 Planned number of subjects to be included
F.4.1In the member state54
F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
As part of the study, participants will receive three-weekly infusions of carboplatin for as long as their cancer is responding and they do not experience significant, unresolving side-effects. Carboplatin is already licensed. Once treatment on study ends (due to disease progression or unresolving toxicity), they will revert to standard management and follow up with their oncology team. The continued care of patient will be at the discretion of the treating clinician.
G. Investigator Networks to be involved in the Trial
G.4 Investigator Network to be involved in the Trial: 1
N. Review by the Competent Authority or Ethics Committee in the country concerned
N.Competent Authority Decision Authorised
N.Date of Competent Authority Decision2017-03-17
N.Ethics Committee Opinion of the trial applicationFavourable
N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
N.Date of Ethics Committee Opinion2016-11-22
P. End of Trial
P.End of Trial StatusGB - no longer in EU/EEA